


# “Promising” Compounds Analysis (July 2024)\*


Novel Compound/Indications (Promising and Watch & Wait) by MOA and Viral Family (N=44)



\*As of July 12, 2024

# Novel Clinical Antiviral Entry Inhibitors\*


Novel Compound/Indications (Promising, Watch & Wait (N=12))



\*As of July 12, 2024; Attachment, Capsid (Rhinovirus), Fusion

# Novel Clinical Antiviral Protease Inhibitors\*


Novel Compound/Indications (Promising, Watch & Wait, Archived (N=18))



\*As of July 12, 2024; Mpro (Coronavirus and Enterovirus)

# Novel Clinical Antiviral Replication Inhibitors\*

## Novel Compound/Indications (Promising, Watch & Wait (N=12))



\*As of July 12, 2024; Polymerase, Endonuclease, Replicase, DENV NS4B

# Novel Clinical Antiviral Assembly-Release Inhibitors\*

Novel Compound/Indications (Promising, Watch & Wait, Archived (N=3))



\*As of July 12, 2024; Neuraminidase



INTREPID ALLIANCE

INTERNATIONAL READINESS FOR PREVENTING INFECTIOUS VIRAL DISEASE

**Interested  
in engaging  
with us?**

We welcome all feedback through [our online portal](#). As with previous listings, developers are invited to submit non-confidential information on their compound candidates. All reports are updated quarterly.

For more information, contact [nina@intrepidalliance.org](mailto:nina@intrepidalliance.org).

 [intrepidalliance.org](https://intrepidalliance.org)

 [linkedin.com/company/intrepid-alliance](https://linkedin.com/company/intrepid-alliance)